Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464707 | 0.84 | ALDH1A1 (0.32) | LMNA | |
| SCHEMBL18522892 | 0.78 | CNR2 (0.41) | MAPTKDM4E | |
| SCHEMBL10220198 | 0.78 | CA1 (0.37) | LMNAMAPTSCN10A | |
| SCHEMBL21133854 | 0.76 | APLNR (0.35) | — | |
| SCHEMBL26022241 | 0.74 | TDP1 (0.42) | LMNANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL23869464 | 0.74 | APLNR (0.31) | — | |
| SCHEMBL21339281 | 0.74 | CA1 (0.32) | LMNAMAPTSMN1; SMN2SCN10A | |
| SCHEMBL17052958 | 0.74 | CA1 (0.34) | LMNAMAPTSCN10A | |
| SCHEMBL18612517 | 0.74 | GBA1 (0.35) | NPC1RAB9AKDM4E | |
| SCHEMBL18523069 | 0.74 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | LMNA 3306/4885NPC1 1604/4885RAB9A 1186/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | LMNA 3306/4885NPC1 1604/4885RAB9A 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.